The following table provides an overview of the latest patents of Amylin Pharmaceuticals, Inc. that has been opposed by its competitors. It provides an insight into the competitive landscape of the industry and highlights the patents that are subject to oppositions.

Patent NumberGrant DateTitleTotal Oppositions
EP2341905Sep 13, 2023Sustained Release Formulations Using Non-Aqueous Carriers1
EP2347762May 8, 2019Exendin For Treating Diabetes And Reducing Body Weight2